Kv1.3 is a voltage gated potassium channel that has been implicated in pathophysiology of multiple sclerosis (MS). In the present study we investigated temporal and cellular expression pattern of this channel in the lumbar part of spinal cords of animals with experimental autoimmune encephalomyelitis (EAE), animal model of MS. EAE was actively induced in female Dark Agouti rats. Expression of Kv1.3 was analyzed at different time points of disease progression, at the onset, peak and end of EAE. We here show that Kv1.3 increased by several folds at the peak of EAE at both gene and protein level. Double immunofluorescence analyses demonstrated localization of Kv1.3 on activated microglia, macrophages, and reactive astrocytes around inflammatory lesions. In vitro experiments showed that pharmacological block of Kv1.3 in activated astrocytes suppresses the expression of proinflammatory mediators, suggesting a role of this channel in inflammation. Our results support the hypothesis that Kv1.3 may be a therapeutic target of interest for MS and add astrocytes to the list of cells whose activation would be suppressed by inhibiting Kv1.3 in inflammatory conditions.
Introduction
Multiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized by chronic inflammation and demyelination of the central nervous system (CNS). Disease is initiated by infiltration of autoreactive immune cells into the CNS, which propel inflammatory reaction against myelinated axons [1] , followed by activation of resident microglial cells which drive further pathology, ultimately leading to degenerative lesions of the brain and spinal cord and loss of neurological functions [2] [3] [4] . Many recent reports suggest that microglia are not responsible just for the recurring neuroinflammation in the later phases of the disease, but they even may participate in the initiation of the neuroinflammatory cascade [2] . The suggestion is corroborated by evidence that activation of microglia precedes the infiltration of peripheral macrophages and the appearance of clinical symptoms of the illness [5] . Moreover, pharmacological blockade of microgliosis prevents development of neurological symptoms in experimental autoimmune encephalomyelitis (EAE), the most commonly used animal model of MS [6] .
Astrocytes are the second resident effector cells with dual roles in MS [7, 8] . Activated astrocytes withdraw their perivascular end feet, which increases the permeability of the blood-brain barrier (BBB) and facilitates the entry of T cells into the CNS [8] . These cells release chemokines which attract immune cells to the sites of tissue damage and produce cytotoxic factors, such as reactive nitrogen and oxygen species, thus acting as mediators of inflammation. Reactive astrocytes also develop hypertrophied processes which impede remyelination and axon regeneration [9] . On the other hand, astrocytes can support anti-inflammatory response and myelin repair by limiting the spread of reactive immune cells and by releasing anti-inflammatory cytokines and chemokines which stimulate migration and differentiation of oligodendrocyte progenitor cells [7] .
The autoimmune-mediated demyelination in MS/EAE, causes alterations in expression and function of several ion channels in axonal membranes, which leads to an increased excitability and augmented intracellular Ca 2+ concentrations, and results in mitochondrial dysfunction and neuronal cell death [10] . Ion channels, including voltage-gated potassium channel Kv1.3, control membrane potential and contribute to several immune and effector cell functions [11] . The Kv1.3 channels open with membrane depolarization and allow outward potassium currents, which counteract the potential change [12] . This channel is best known for its roles in immune cells like T [13] [14] [15] and B cells [16, 17] , macrophages [18, 19] and dendritic cells [20, 21] . In the CNS, the channel is also present in microglia [22] [23] [24] and select population of central and peripheral neurons [25, 26] .
A number of clinical and experimental studies show predominant expression of Kv1.3 at subpopulations of infiltrated T cells and macrophages [15] . The upregulation is particularly prominent at activated macrophages [27, 28] and subpopulations of Th17 and myelin-reactive effector memory T cells (T EM ), which show several-fold increase in number of Kv1.3 channel molecules in respect to the resting state [13] . In addition, Kv1.3 channels play pivotal role in several aspects of microglial activation [29] , including proliferation [30] , cell shape transition, migration [31] , NADPH oxidase-dependent respiratory burst [22] and cytokine release [32] . Finally, the role of Kv1.3. in the pathophysiology of MS/EAE is demonstrated with Kv1.3 channel blockers which relieve the autoimmune neuroinflammation, by preserving the integrity of BBB [33] , reducing activation of T EM cells [34] and abolishing respiratory burst in activated microglia and subsequent deleterious effects of these cells on neuronal survival [23] . These findings make Kv1.3 valuable potential therapeutic target for immunosupression in MS and EAE [34] .
It is well known that the Kv1.3 channels are fundamentally involved in the regulation of the immune response of several immune cell types implicated in the pathophysiology of MS/EAE [10] and currently, several selective Kv1.3. channel blockers are validated in the preclinical studies for their performance in MS [35] . Most of the basic research in EAE and clinical research in MS is focused on the underlying mechanism by which Kv1.3. channel blockers suppress infiltrated T cell activation and relieve autoimmune symptoms. However, little is known about localization and expression of Kv1.3 by resident glial cells in the spinal cord, both in physiological conditions and in EAE. Therefore, in the present study we have analyzed expression and cellular distribution of Kv1.3 in the lumbosacral spinal cord of Dark Agouti rats (DA) during EAE. We have demonstrated that besides infiltrated macrophages and reactive microglia, Kv1.3 channel protein is expressed by reactive astrocytes during the symptomatic phase of the disease. The role of Kv1.3 channels in function of fully developed reactive astrocytes was assessed in the subsequent in vitro study performed on C6 astrocytoma cell line in the presence of selective blocker of Kv1.3. channels agitoxin-2 (AgTx2). It was demonstrated that Kv1.3 channel blockade did not affect C6 morphology, but interfered with induction of proinflammatory genes in the cells.
Materials and Methods

Experimental Animals
Two-month old female rats of DA strain were used throughout the experiments. Experimental procedures were approved by Ethical Committee for the Use of Laboratory Animals of Institute for Biological Research "Sinisa Stankovic" (Belgrade, Serbia), in compliance with EEC Directive (2010/63/EU) on the protection of animals used for experimental and other scientific purposes. Animals were housed (3-5/cage) under standard conditions (23 ± 2 °C, 50-60% relative humidity, 12 h/12 h light/dark cycle), with free access to food and water. During the period of paralysis, animals were given water by hand.
Induction of EAE and Assessment of Disease Severity
Animals were randomly divided into control (n = 10) and EAE group (n = 30). EAE was induced by subcutaneous injection of the spinal cord homogenate (syngenic spinal cords homogenized in 50% w/v saline) mixed with an equal volume of complete Freund's adjuvant supplemented with 0.5 mg/ml Mycobacterium tuberculosis (CFA; Sigma, St. Louis, MO, USA).
All animals were weighed and examined daily, while EAE group was graded for neurological signs of EAE for 29 days post immunization (dpi). Two independent researchers unfamiliar with the experiment protocol and experimental groups examined the animals. Disease score was evaluated according to standard 0-5 EAE grading scale: 0-without symptoms; 1-atony of tail; 2-hind limb weakness; 3-hind limb paralysis; 4-tetraplegic; 5-moribund state or death. Average disease score and weight were calculated for every time point. First signs of the disease appeared on 7 dpi, which was designated as disease onset (E o ). Peak of the disease occurred at 14 dpi (E p ), after which the animals slowly recovered, with 29 dpi used as the end of disease (E e ). At these time points animals were sacrificed and spinal cord tissue was used for analyses.
Tissue Preparation
Deep anesthesia was induced with Zoletil®50 (Virbac, France; 30 mg/kg i.p.), animals were perfused intracardially with ice cold saline solution after which the animals were decapitated. Age-matched animals that were not immunized were used as controls. Spinal cords were isolated with hydraulic extrusion [36] and lumbar regions of the spinal cord were quickly dissected on ice.
Quantitative Real-Time PCR
Excised lumbar segments of the spinal cords were placed in sterile tubes with RNAlater stabilization solution (Invitrogen, Carlsbad, CA, USA) and stored at − 80 °C until all groups were collected. In cell culture experiments, cells of C6 glioma cell line were treated for 4 h with AgTx2, a pore blocker of Kv1.3 channels, and IFN-γ and then harvested. Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following standard procedure. Concentration of RNA was determined by measuring absorbance at 260 nm, while purity of the sample was evaluated by the ratio of absorbance measurements at 260/280 nm and 260/230 nm. From each sample 1 µg of RNA was transcribed to cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR (qRT-PCR) analyses were performed using SYBR Green PCR master mix (Applied Biosystems, Foster City, CA, USA) and designated primers ( 
Western Blot
Isolated lumbar regions of spinal cords were pooled (three per group) for plasma membrane preparation, as previously described [37] . Briefly, tissue homogenization was performed on ice in 5 mM Tris buffer, pH 7.4 that contains 0.32 M sucrose, with subsequent centrifugation at 1000×g for 10 min, at 4 °C. The precipitate that contained residues of blood and cell nuclei was discarded and the supernatant was centrifuged in ultracentrifuge at 12,000×g for 30 min, at 4 °C. The resulting precipitate was resuspended and homogenized in 5 mM Tris, pH 7.4 with protease inhibitors (Roche, Penzberg, Germany). Isolated plasma membranes were stored at − 80 °C until all the groups were collected. Protein concentration in all samples was determined with BCA protein assay kit (Pierce Biotechnology, Rockford, IL, USA), following manufacturer's instructions. Equal amounts of protein (20 µg) were loaded onto 7.5% polyacrylamide gels and separated electrophoretically under reducing conditions at 100-120 V. Resolved proteins were transferred to PVDF membranes (Roche, Penzberg, Germany) for 1 h, at 100 V. Unspecific binding was blocked with 5% bovine serum albumine (BSA, Sigma-Aldrich, Munich, Germany) in Tris buffered saline with 0.05% Tween 20 (TBST) (20 mM Tris, pH 7.6, 136mMNaCl, 0.1% Tween 20) for 1 h at room temperature (RT). The membranes were incubated with Kv1.3 primary antibody (Table 2) in TBST, overnight at 4 °C. On the next day, the blots were washed in TBST three times for 10 min and then incubated with appropriate HRP-conjugated secondary antibody (Table 2 ) for 2 h, at RT. Luminol (Sigma-Aldrich, Munich, Germany) was used 
Immunofluorescence Staining
For immunofluorescence studies isolated lumbar sections of the spinal cord were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PBS), pH 7.4 overnight at 4 °C and then cryoprotected in increasing solutions of sucrose (10-30% in 0.1 M PBS, pH 7.4). Afterward, the tissue was frozen in 2-methyl butane and stored at − 80 °C. Coronal sections (20 µm thick) were cut on cryotome and 5-6 consecutive sections were mounted on a glass slide. The slices were left to dry for 2 h at RT and were kept at − 20 °C until immunofluorescent staining. Before immunostaining the slides were first rinsed in PBS and then immersed in 0.25% Triton X-100 in PBS for 15 min. After washing the slides in PBS for 3 × 5 min, unspecific binding was blocked with 5% BSA (Sigma-Aldrich, Munich, Germany) in PBS for 1 h at RT. Incubation with primary antibody for Kv1.3 (Table 2) was done overnight at 4 °C. On the next day, the slides were washed for 3 × 5 min in PBS and then incubated with secondary anti-rabbit Alexa Fluor 555 fluorescent antibody (Table 2) for 2 h at RT. After washing in PBS, primary antibodies for specific cell markers were used: glial fibrillary acidic protein (GFAP) and vimentin, as markers of astrocytes, ED1, marker of activated macrophages/microglia, and Iba1, marker of microglia. Incubation with these primary antibodies was also performed overnight, at 4 °C. After PBS wash, the slides were incubated with the appropriate secondary Alexa Fluor 488 antibodies. Nuclei were stained with Hoechst 33342 for 10 min at RT, and after thorough washing with PBS, sections were mounted with Mowiol (Calbiochem, Millipore, Germany). Immunohistochemistry was performed with appropriate controls, as suggested by Burry and Hewitt with coworkers [38, 39] . Appropriate negative control with blocking peptide for Kv1.3 (Alomone, Jerusalem, Israel) was done to ensure antibody specificity.
Immunofluorescence was captured with Zeiss Axiovert fluorescent microscope (Zeiss, Jena, Germany), using ×40 magnifications or ×63 magnification and Apotome system for obtaining optical sections.
Image Analysis and Quantification
Sections of the spinal cord labeled with Kv1.3/Iba1 and Kv1.3/GFAP were used for quantification of expression of this channel by microglia and astrocytes. Quantification was performed using ImageJ software package (National Institutes of Health, Bethesda, Maryland, USA), as previously described [40] . Briefly, sections from each group were divided into four quadrants-dorsal, ventral and right and left lateral, and two to four non-overlapping images of each quadrant were taken. 
Cell Culture and Treatment
The C6 astrocytoma cell line is a widely used model for analysis of astrocytes [41, 42] . The C6 cells express many astrocyte specific markers, including GFAP and S-100B protein [43, 44] . The cells were cultured under standard conditions (37 °C, 95% air/5% CO 2 ), in RPMI 1640 medium (GE Healthcare Life Sciences, Freiburg, Germany) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Waltham, MA, USA) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Upon reaching 80% confluence, cells were detached with 0.1% trypsin-EDTA and seeded into appropriate sterile dishes and incubated overnight. Cells were treated with 5 nM AgTx2 (Sigma-Aldrich, Munich, Germany) 30 min prior to stimulation with 500 U/ml IFN-γ (R&D Systems, Minneapolis, USA) for 4 h for qRT-PCR and 24 h for other analyses. For qRT-PCR analysis, 2.5 × 10 5 C6 cells were seeded in 6-well plates, treated as described and then collected with Trizol reagent. Further isolation of RNA, cDNA synthesis and qRT-PCR analysis was performed as described in PCR section of "Material and Methods".
Analysis of Cell Viability and Cell Morphology
Screening of C6 cell line viability and morphology was performed with xCELLigence Real-Time Cell Analyzer Single Plate instrument (RTCA SP, ACEA Biosciences, San Diego, ), left to adhere overnight, pretreated with 5 nM AgTx2 and stimulated with 500 U/ml IFN-γ for 24 h, as described. During the whole experiment Cell Index was recorded (in 5 min intervals) and the results are normalized to time of treatment with IFN-γ and expressed as Normalized Cell Index. Cell index value of RPMI 1640 medium was the background measurement that was subtracted from all the results.
To analyze cell morphology in further detail F-actin was stained with Alexa Fluor 555 phalloidin (Invitrogen, Carlsbad, CA, USA). C6 cells were seeded on glass cover-slips (Ø25 mm) at the density of 6 × 10 4 and put in 35 mm dishes (Sarstedt, Newton, NC, USA). Treatment with IFN-γ and AgTx2 lasted for 24 h after which the cells were fixed with 4% paraformaldehyde for 20 min at 4 °C. After a wash with PBS, glass coverslips were put in 0.25% Triton X-100 (SigmaAldrich, Munich, Germany) to permeabilize the cell membrane and allow for staining of intracellular F-actin (dilution of 1:50 in PBS) for 30 min at RT. Hoechst 33342 (5 µg/ml, Life Technologies, Invitrogen, Carlsbad, CA, USA) was used for 5 min at RT to stain cell nuclei. Coverslips were mounted with Mowiol (Calbiochem, Darmstadt, Germany) and images acquired with confocal laser scanning microscope (LSM 510, Carl Zeiss GmbH, Jena, Germany) using Ar Multi-line (457, 478, 488, and 514 nm) and HeNe (543 and 633 nm) lasers, and 63 × DIC oil and 100 × DIC oil objectives. Images were analyzed using AxioVisionRel 4.9.1 software (Zeiss, Jena, Germany). Mean cell surface area was determined in ten areas (146 × 146 µm) per cover-slip, with two cover-slips per group, in three independent sets of experiments.
Data Analysis
Results are expressed as mean values ± SEM, except for disease score assessment where the results are presented as mean ± standard deviation. Statistical significance was analyzed with GraphPad Prism software. The results were analyzed with One-Way ANOVA and Bonferroni post-hoc test. Values of p < 0.05 were considered to be statistically significant.
Results
Time-Course Changes of Clinical Signs During EAE
EAE was induced in immunized animals with 100% incidence and monophasic course. Time-course changes in disease score and animal weight are shown in Fig. 1 . First clinical signs appeared at 7 dpi, reached a maximum at 14 dpi, after which the animals slowly recovered until 29 dpi. These time points were taken as onset (E o ), peak (E p ) and end of disease (E e ). Development of clinical signs was concurrent with body weight loss, which was most pronounced at E p .
Kv1.3 Is Upregulated at the Peak of EAE
Expression of Kv1.3 in the lumbosacral region of the spinal cord during EAE was evaluated with qRT-PCR and Western blot (Fig. 2) . The expression levels of Kv1.3 corresponded to the rise in clinical manifestations of EAE. Almost twofold increase in Kv1.3-mRNA (KCNA3, Fig. 2a ) and about four-fold increase in the protein abundance (Fig. 2b) were demonstrated at the peak of illness. To investigate which cells were responsible for the observed Kv1.3 upregulation, in the next set of experiments we performed double immunofluorescence labeling for Kv1.3 and cell-specific markers. 1-atony of tail; 2-hind limb weakness; 3-hind limb paralysis; 4-tetraplegic; 5-moribund state or death. Average disease score and body weight were calculated for every time point. Progress of EAE was associated with body weight loss, which was most pronounced at the peak of disease (black line). EAE animals were sacrificed at the onset (D7), peak (D14) and end (D29) of disease. Data are expressed as the mean clinical score ± SEM (10 rats per group). (Color figure  online) 
Expression of Kv1.3 Is Upregulated on Activated Microglia and Macrophages During the Progression of EAE
Microglial expression of Kv1.3 was assessed by double immunofluorescence labeling of Kv1.3 with microglial marker Iba1 (Fig. 3) . At control sections, rare Iba1 + cells had small cell bodies and numerous ramified processes and did not express Kv1.3 (arrowheads, Fig. 3a-c, m) . From the onset to the peak of disease activation of microglia evolved, which was reflected in increasing number of Iba1 + cells and a noticeable change in the morphology, with enlarged cell bodies and processes that became fewer and thicker (Fig. 3d-i) . At E o and E p 90% of Iba1 positive microglial cells expressed Kv1.3 (arrows, Fig. 3d-f, g-i, m) . Highest number of these Kv1.3 + Iba1 + cells was found in inflammatory infiltrates at the peak of disease (Fig. 3g-i) . At the end of disease, percentage of Kv1.3 expressing microglial cells was reduced to 65% of total Iba1 + cells (arrows, Fig. 3j-l,  m) . Expression of Kv1.3 at E p and E e was also noticed on cells with elongated processes that resembled astrocytes (arrowheads, Fig. 3g-i, j-l) .
In control sections ED1 + cells were not observed, however at onset and peak of disease many ED1 + cells expressed Kv1.3 (Fig. 4) . At E e amoeboid ED1 + cells were largely devoid of Kv1.3, implying that Kv1.3 expression depends on the functional status of these cells.
Kv1.3 is Expressed on Reactive Astrocytes During the Progression of EAE
Subsequent double immunofluorescence labeling combining Kv1.3 and astrocyte markers GFAP and vimentin revealed that activated astrocytes abundantly expressed the channel (Figs. 5, 6 ). In control sections fibrous astrocytes with thin processes positive for GFAP and vimentin, did not express Kv1.3 (Figs. 5a-c, m, 6a-c (Fig. 5m) . These results indicate that Kv1.3 plays a role in astrocytic pathology during the course of EAE and that its expression on reactive astrocytes may contribute to the overall upregulation of the channel protein at the peak of disease.
Blockade of Kv1.3 Does Not Prevent IFN-γ Induced Alterations in C6 Cell Morphology
The role of Kv1.3 in astrocyte function was investigated in C6 rat astrocytoma cell line, activated with IFN-γ [45, 46] , in the absence and presence of selective Kv1.3 channel blocker AgTx2. Changes in the cell viability and morphology were quantified by noninvasive electrical impedance monitoring with xCelligence® RTCA DP instrument (Fig. 7a) . The resulting cell index gradually increased in all groups during the 24 h the cells were monitored. Group treated with IFN-γ had cell index values that were higher compared to control, pointing to changes in morphology as a consequence of activation. Cells pretreated with AgTx2 and then stimulated with IFN-γ had lower cell index values compared to IFN-γ alone, however this difference was not statistically significant. The role of Kv1.3 in C6 cell morphology was further studied by analyzing the microfilament organization in the cells activated with IFN-γ, in the absence or presence of AgTx2 (Fig. 7b) . Untreated cells had polygonal shape with scattered stress fibers oriented in different directions. Following treatment with IFN-γ, the cells surface area considerably increased (Fig. 7c) , together with rearrangement of the microfilaments. The polymerization of F-actin fibers to stress fibers increased and these IFN-γ induced changes in cell morphology were not prevented with AgTx2 pretreatment.
Blockade of Kv1.3 Suppresses Expression of Proinflammatory Mediators in C6 Cells
We further tested whether the blockade of Kv1.3 interferes with the induction of proinflammatory genes in C6 cells stimulated with IFN-γ. As presented in Fig. 8 , the abundance of transcripts encoding for TNF-α, IL-6 and CCL2 significantly increased up to 190, 250 and 275% respectively, in C6 cells treated with IFN-γ in comparison to non-treated cells, whereas the mRNA abundances were markedly reduced by Kv1.3 channel blocker. Specifically, AgTx2 reversed the cytokine-induced increase in TNF-α and considerably suppressed CCL2, but did not interfere with production of IL-6. These results suggest that Kv1.3-mediated K + currents and the resulting membrane repolarization may have a role in the induction of proinflammatory genes by activated astrocytes in vitro.
Discussion
In the present study we evaluated the expression pattern of Kv1.3 on gene and protein level in spinal cords of animals during EAE. Cell specific profiling was performed to assess cell types expressing Kv1.3 at different time points in the disease progression. We have shown that in addition to the microglial/macrophages expression, reactive astrocytes in rat spinal cord express Kv1.3 at the peak and end of disease. Inhibition of Kv1.3 in activated astrocytes in vitro suppressed gene expression of proinflammatory markers, associating Kv1.3 with proinflammatory role of astrocytes.
Kv1.3 has been in the focus of MS research in recent years, predominantly for its important role in T EM cells that are main mediators of autoimmunity. Terminally differentiated autoantigen specific T EM cells with CCR7 − and CD45RA − phenotype upregulate Kv1.3 and migrate to inflamed tissues where they perform effector functions and contribute to disease progression [13] . Kv1.3 is involved in T cell activation by preventing membrane depolarization and keeping the driving force for entry of Ca 2+ that activates signaling cascades leading to cytokine production and proliferation of T cells. These processes are enabled with efflux of K + through Kv1.3 [12] . Administering Kv1.3 antagonist in vivo alleviated symptoms of EAE [33, [47] [48] [49] [50] [51] and was shown to maintain integrity of BBB [33] . Additionally, Kv1.3 knockout mice showed lower incidence and severity of EAE compared to wild type animals [52] .
Although the role of Kv1.3 in MS has been studied, changes in its cellular and temporal expression have not been investigated in the spinal cord in animal models of MS, such as EAE. We used the EAE model in DA rats, previously reported to be highly susceptible in developing the disease, although the changes are only detectable in the spinal cord. Our results show that Kv1.3 is expressed at gene but scarcely at protein level in spinal cords of healthy control animals, as was determined with qRT-PCR and western blotting/double immunofluorescence studies, respectively. Our results are in agreement with a previous study that identified KCNA3 mRNA but failed to detect protein expression in the spinal cords of healthy Wistar rats [53] . In our study, several fold upregulation of Kv1.3 was detected at the peak of disease on both protein and mRNA level. With the resolution of EAE, expression of Kv1.3 subsided. Double immunofluorescence studies demonstrated how these changes are correlated to its expression pattern on different cell types in the spinal cord of EAE animals.
As professional APCs, infiltrated macrophages play a key role in EAE, producing an array of cytokines and influencing T cell activation [2] . Kv1.3 activity influences the degree of macrophage activation and increase in Kv1.3 expression in activated macrophages was determined in cell culture [19, 54] and in MS brain inflammatory infiltrates [15] . In our study we showed disease phase dependent changes in Kv1.3 expression in the inflammatory infiltrates with double staining for ED1, marker of activated microglia and macrophages. At the onset and peak of the disease, expression of Kv1.3 was observed in a subset of ED1 + cells. However, at the end of disease no ED1 + cells expressed Kv1.3, suggesting that this channel has a role in macrophages for a limited time frame. This role could be in relation to formation of foam cells. It was previously shown that Kv1.3 is involved in cholesterol metabolism and participates in differentiation of macrophages to foam cells [55] . Foamy macrophages ingest myelin and are characteristic for demyelinating lesions in MS/EAE, as we have shown previously [56] . They appear to have a complex role in disease progression as they express both pro-and anti-inflammatory markers [57, 58] . Considering
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that activation of Kv1.3 in macrophages has been linked to their proliferation and NO production [18] , inhibiting Kv1.3 at the onset and peak of EAE, corresponding to symptomatic phase of MS, could be beneficial for disease progression.
Furthermore, we showed an increase in Kv1.3 expression in microglia in spinal cords of EAE animals. Specifically, we demonstrated that at the onset and peak of the disease 90% of Iba1 + cells expressed Kv1.3. This percentage decreased to 65% by the end of disease, and the number of activated microglia subsided. We can conclude that Kv1.3 has a role in activated microglia throughout the disease. Role of Kv1.3 in pro-inflammatory activation of microglia has been described in vitro [22, 23, 59] . Recently, Nguyen et al. showed that microglia with pro-inflammatory phenotype had higher Kv1.3 currents concluding that inhibiting Kv1.3 has a selective effect on pro-inflammatory subtype of microglia [60] . In view of previous studies, we confirm the expression of Kv1.3 in microglia in our EAE model and we propose that inhibiting this channel in microglia would be valuable throughout the disease.
Considering that astrocytes have multiple functions in the pathophysiology of MS and directly contribute to neuroinflammation [8, 61] , we further investigated whether Kv1.3 is expressed on astrocytes in EAE model. As in other neurodegenerative diseases, during the course of MS and EAE astrocytes become activated, proliferate and change their morphology. Their cell bodies become bigger and processes thicker and longer, eventually forming the glial scar [62] . Their reaction depends on the proximity to the demyelinating lesions, with astrocytes near the lesion site exhibiting a stronger response. Even though astrocytes have many deleterious roles in MS they also show some protective characteristics and help in promoting remyelination [9] . In this study we find for the first time that Kv1.3 is expressed on reactive astrocytes around demyelination sites in spinal cords of EAE animals. This phenomenon was most pronounced at the peak and end of disease where 60% of astrocytes expressed Kv1.3. To corroborate the expression of Kv1.3 on activated astrocytes we performed double immunofluorescence analyses with two astrocytic markers, GFAP and vimentin. GFAP is the typical marker of mature astrocytes and vimentin is characteristic intermediate filament of immature astrocytes, however both are upregulated in activated astrocytes in different neurodegenerative diseases [63, 64] . Vimentin has been shown to be increased in a subpopulation of reactive astrocytes as the inflammation subsides in EAE [65] . In our model we found that expression of Kv1.3 coincided with both of these markers, suggesting that this channel is expressed on different subpopulations of astrocytes. Although our immunofluorescence analyses show expression of Kv1.3 on astrocytes and microglia at the end of disease, results from qRT-PCR and western blot analyses demonstrate that highest increase of both gene and protein expression is at the peak of disease. We assume this is because the highest number of inflammatory cells occurs at the peak of disease, and a large subset of these cells express Kv1.3, including T cells that were not the subject of this study but have been studied previously [12, 13] . Kv1.3 was previously detected in astrocytes in C6 cells in culture [66] , in mixed glial cultures and astrocytes in the corpus callosum of animals that suffered traumatic brain injury, where its expression was moderate compared to microglia [67] . Bearing in mind that astrocytes have dual roles in MS and EAE we examined how blockade of Kv1.3 affects their activation in vitro. Blocking Kv1.3 did not affect the cell size of activated astrocytes; however it suppressed expression of proinflammatory markers TNF-α and CCL2. One of the most detrimental astrocytic processes in MS and EAE is the production of proinflammatory cytokines and chemokines. Increase in TNF-α was detected in cerebrospinal fluid of MS patients [68] and it was shown that TNF-α levels are in direct proportion to extent of demyelination in MS [69] . TNF-α from astrocytes suppresses expression of glutamate transporters, undermining astrocytic glutamate intake and thus promoting neuronal degeneration [70] . Similarly, chemokine CCL2 is increased in astrocytes in MS lesions and EAE, and has an integral part in mobilizing immune cells to CNS [71, 72] . Furthermore, CCL2 −/− mice are protected from EAE and it has been suggested that CCL2 has an important function at the onset of EAE [73] . Considering that inhibition of Kv1.3 leads to a decrease in expression of these proinflammatory markers we can conclude that Kv1.3 has a role in proinflammatory actions of astrocytes in neuroinflammation.
Collectively, our data extend the existing knowledge on the Kv1.3 role in EAE by showing specific expression profile of Kv1.3 in spinal cords of EAE animals and pointing to a proinflammatory role of this channel in activated astrocytes that has not been described up to now. Kv1.3 expression was upregulated on gene and protein level during EAE and this upregulation correlated with clinical disease score. We found that this was a consequence of Kv1.3 upregulation 
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